News & Updates
Showing Multidisciplinary articles
Showing
Palbociclib–bazedoxifene combo for HR+/HER2− breast cancer succeeds in early trial
Treatment with the combination of palbociclib plus bazedoxifene demonstrates clinical efficacy while having an acceptable safety profile in treatment-experienced patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer, according to the results of a phase Ib/II study.
Acalabrutinib-based chemo-free triplet shows high rates of MRD-negative CR in 1L MCL study
First-line (1L) acalabrutinib in combination with lenalidomide and rituximab (ALR) has demonstrated high rates of minimal residual disease (MRD)–negative complete remission (CR) in patients with mantle cell lymphoma (MCL), including patients with TP53 mutations, in a single-arm phase II trial reported at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Does fMRI neurofeedback improve symptoms, cognition in children with ADHD?
Nonpharmacological treatment with functional magnetic resonance imaging neurofeedback (fMRI-NF) of the right inferior frontal cortex (rIFC) does not seem effective in improving clinical symptoms or cognition in boys with attention deficit hyperactivity disorder (ADHD), reports a recent study.
Do supplements measure up to statins for lipid-lowering?
In individuals with increased 10-year risk for ASCVD*, rosuvastatin 5 mg significantly reduced LDL-C** and other lipid and inflammatory biomarkers compared with placebo and six widely used heart health supplements, results from the SPORT*** trial have shown.
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.